Home > Insider Trading > Filing (0000078003-20-000023)

Filing Details

Accession Number:: 0000078003-20-000023
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-16 19:15:07
Reporting Period:: 2020-03-16

Accepted Time:: 2020-03-16 19:15:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Imara Inc.	IMRA	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
78003	Pfizer Inc	235 E 42Nd St New York NY 10017		No	No	Yes	No
1776087	Pfizer Ventures (Us) Llc	235 East 42Nd Street New York NY 10017		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-16	76,003	$0.00	76,003	No	4	C	Direct
Common Stock	Acquisiton	2020-03-16	868,467	$0.00	868,467	No	4	C	Indirect	By Pfizer Ventures (US) LLC
Common Stock	Acquisiton	2020-03-16	300,752	$0.00	1,169,219	No	4	C	Indirect	By Pfizer Ventures (US) LLC
Common Stock	Acquisiton	2020-03-16	312,500	$16.00	1,481,719	No	4	P	Indirect	By Pfizer Ventures (US) LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	By Pfizer Ventures (US) LLC
No	4	C	Indirect	By Pfizer Ventures (US) LLC
No	4	P	Indirect	By Pfizer Ventures (US) LLC

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Preferred Stock	Disposition	2020-03-16	478,749	$0.00	76,003	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-03-16	5,470,492	$0.00	868,467	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-03-16	1,894,444	$0.00	300,752	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect

Footnotes

On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date.
On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.
On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein.
Pfizer Ventures (US) LLC purchased 312,500 additional shares of common stock in the Issuer's initial public offering at the initial public offering price of $16.00 per share.